Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) has been assigned an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Brokerages have set a twelve-month consensus price objective of $2.13 for the company and are expecting that the company will post ($0.06) EPS for the current quarter, according to Zacks. Zacks has also assigned Diffusion Pharmaceuticals an industry rank of 80 out of 255 based on the ratings given to its competitors.
Separately, HC Wainwright reiterated a “buy” rating and issued a $1.25 price target on shares of Diffusion Pharmaceuticals in a report on Monday, August 20th.
NASDAQ DFFN remained flat at $$0.38 on Wednesday. 30,734 shares of the company’s stock were exchanged, compared to its average volume of 462,035. The company has a market cap of $21.83 million, a P/E ratio of -0.33 and a beta of -1.94. Diffusion Pharmaceuticals has a one year low of $0.31 and a one year high of $2.97.
Diffusion Pharmaceuticals (NASDAQ:DFFN) last announced its quarterly earnings results on Monday, August 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. As a group, analysts forecast that Diffusion Pharmaceuticals will post -0.42 EPS for the current year.
About Diffusion Pharmaceuticals
Diffusion Pharmaceuticals Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke.
Featured Story: Exchange-Traded Funds (ETFs)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.